ArticleInfection & chemotherapy2025
Direct Out-of-Pocket Costs of Nirsevimab
Article in Infection & chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring parental awareness and willingness to use monoclonal antibodies for respiratory syncytial virus prevention.Human vaccines & immunotherapeutics · 2025Article
- Feasibility and Acceptability of Respiratory Syncytial Virus Vaccination in Mothers for Infant Protection at Edward Francis Small Teaching Hospital, the Gambia.Journal of epidemiology and global health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) remains a significant health burden in infants, with limited prevention options. Palivizumab, the monoclonal antibody (mAb) currently used for high-risk infants, requires a five-dose regimen, costing caregivers 47,260-642,000 Korean won (KRW) under the health insurance system, depending on the remaining season and infant's weight. Nirsevimab, the first approved long-acting RSV mAb, offers season-long protection with a single dose and costs 435,000-600,000 KRW. Direct cost comparisons indicate that nirsevimab might be more economical for infants born between April and November. Policy adjustments are needed to ensure equitable RSV protection through national immunization programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.